Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$19.54
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
ArriVent BioPharma Analyst Ratings and Price Targets | NASDAQ:AVBP | Benzinga
ArriVent BioPharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for ArriVent BioPharma Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B. Riley Securities
Guggenheim
HC Wainwright & Co.
Citigroup
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for ArriVent BioPharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/20/2025 | Buy Now | — | B. Riley Securities | Kalpit Patel40% | → $37 | Initiates | → Buy | Get Alert |
| 03/10/2025 | Buy Now | — | Guggenheim | Michael Schmidt56% | → $45 | Initiates | → Buy | Get Alert |
| 03/07/2025 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $39 → $39 | Reiterates | Buy → Buy | Get Alert |
| 01/22/2025 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $36 → $39 | Maintains | Buy | Get Alert |
| 11/15/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | — | Citigroup | Yigal Nochomovitz55% | $30 → $36 | Maintains | Buy | Get Alert |
| 09/10/2024 | Buy Now | — | Oppenheimer | Jeff Jones33% | $35 → $39 | Reiterates | Outperform → Outperform | Get Alert |
| 09/10/2024 | Buy Now | — | Goldman Sachs | Corinne Johnson30% | $28 → $38 | Maintains | Buy | Get Alert |
| 09/10/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $30 → $36 | Maintains | Buy | Get Alert |
| 08/16/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $25 → $30 | Maintains | Buy | Get Alert |
| 08/15/2024 | Buy Now | — | Oppenheimer | Jeff Jones33% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 06/06/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns42% | → $25 | Initiates | → Buy | Get Alert |
| 02/20/2024 | Buy Now | — | Citigroup | Yigal Nochomovitz55% | → $30 | Initiates | → Buy | Get Alert |
| 02/20/2024 | Buy Now | — | Jefferies | Kelly Shi42% | → $35 | Initiates | → Buy | Get Alert |
| 02/20/2024 | Buy Now | — | Goldman Sachs | Corinne Johnson30% | → $27 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for ArriVent BioPharma (AVBP) stock?
The latest price target for ArriVent BioPharma (NASDAQ:AVBP) was reported by B. Riley Securities on March 20, 2025. The analyst firm set a price target for $37.00 expecting AVBP to rise to within 12 months (a possible 89.36% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ArriVent BioPharma (AVBP)?
The latest analyst rating for ArriVent BioPharma (NASDAQ:AVBP) was provided by B. Riley Securities, and ArriVent BioPharma initiated their buy rating.
When was the last upgrade for ArriVent BioPharma (AVBP)?
There is no last upgrade for ArriVent BioPharma
When was the last downgrade for ArriVent BioPharma (AVBP)?
There is no last downgrade for ArriVent BioPharma.
When is the next analyst rating going to be posted or updated for ArriVent BioPharma (AVBP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ArriVent BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ArriVent BioPharma was filed on March 20, 2025 so you should expect the next rating to be made available sometime around March 20, 2026.
Is the Analyst Rating ArriVent BioPharma (AVBP) correct?
While ratings are subjective and will change, the latest ArriVent BioPharma (AVBP) rating was a initiated with a price target of $0.00 to $37.00. The current price ArriVent BioPharma (AVBP) is trading at is $19.54, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.